Vitro Biopharma Revenue and Competitors

Golden, CO USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Vitro Biopharma's estimated annual revenue is currently $2.5M per year.(i)
  • Vitro Biopharma's estimated revenue per employee is $155,000

Employee Data

  • Vitro Biopharma has 16 Employees.(i)
  • Vitro Biopharma grew their employee count by -20% last year.

Vitro Biopharma's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
Member Board Directors | Chief Regulatory & Scientific StrategistReveal Email/Phone
3
Chief Scientific OfficerReveal Email/Phone
4
Chief Operating OfficerReveal Email/Phone
5
Chief Financial OfficerReveal Email/Phone
6
Lab Director/Clinical ConsultantReveal Email/Phone
7
Logistics ManagerReveal Email/Phone
8
Laboratory ManagerReveal Email/Phone
9
Quality Control SpecialistReveal Email/Phone
10
Clinical Data AnalystReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1.7M110%N/AN/A
#2
$2.8M1813%N/AN/A
#3
$70.2M453-1%N/AN/A
#4
$1.6M10-66%N/AN/A
#5
$3.7M24-8%N/AN/A
#6
$2.9M3728%N/AN/A
#7
$3.1M2025%N/AN/A
#8
$2.5M16-20%N/AN/A
#9
$9.1M590%N/AN/A
#10
$4.2M27-7%N/AN/A
Add Company

What Is Vitro Biopharma?

Vitro Biopharma, a publicly traded biotechnology firm (OTCQB:VODG), develops technology and products derived from adult stem cells and is currently focused on mesenchymal stem cells (MSCs). MSCs have numerous applications in treatment of a variety of medical conditions, including injuries or diseases of the joints, heart, kidney, liver and lung failure, MS, stroke, cancer, hearing loss, and various other regenerative medicine applications. MSCs may be derived from an individual patient, expanded and then transplanted back to that patient to treat injury or disease through regeneration or repair of specific cells. Vitro manufactures and distributes to global markets a series of products for use by scientists and companies developing clinical applications of MSCs. Our products include: a) Cell Culture Media -We offer various formulations of MSCs and primary cell cultures with numerous competitive advantages. b) Various Cell Lines -Our cell lines include Umbilical Cord Blood derived MSCs, Adipose derived MSCs, Fluorescent Labeled MSCs, Cancer Associated Fibroblasts (CAFs), and Differentiated MSCs c) Brain-Grow Technologies -Neurological and Inflammatory Biomarker Profiling and Nutraceutical Recovery Packages

keywords:N/A

N/A

Total Funding

16

Number of Employees

$2.5M

Revenue (est)

-20%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$2.8M16-6%N/A
#2
$2.4M16-33%N/A
#3
$1.4M16N/AN/A
#4
$1.4M16N/AN/A
#5
$3.3M170%N/A